Gliptin drugs have similar mechanism of action, the difference in glucose-lowering effect is not significant, can be selected according to renal function, adverse reactions and other personal circumstances, should follow the doctor’s instructions for medication. Glicliptin belongs to the dipeptidyl peptidase-IV inhibitor class of hypoglycemic drugs, which can promote insulin secretion by increasing the level of GLP-1 in the body, and is mainly used for the treatment of type 2 diabetes mellitus. The representative drugs of gliptins include selegiline, vigliptin, saxagliptin, and liragliptin, etc. These drugs have the same mechanism of action and the difference in glucose-lowering effect is not big. Rigliptin can usually be used in all patients with chronic kidney disease; selegiline should be reduced in dosage when used in patients with poor renal function; saxagliptin and vigliptin are not recommended for patients with poor renal function. Patients who need to be treated with gliptins should use the medication under the supervision of a doctor.